November 19, 2009

National Institute of Environmental Health Sciences

Rodbell Auditorium, Rall Building

111 T.W. Alexander Drive, Research Triangle Park, NC

Technical Reports (TR) Scheduled for Review

- TR 564 1–Bromopropane (CASRN 106–94–5)
 - Previously used as an intermediate in the production of pesticides, quaternary ammonium compounds, flavors, and fragrances. Introduced as a less toxic replacement for methylene chloride in emissive applications such as vapor and immersion degreasing operations and critical cleaning of electronics and metals. Used as a relatively nonflammable, nontoxic, fastdrying, and inexpensive solvent for adhesive resins, and as a replacement for ozone-depleting refrigerants.
- TR 565 Milk Thistle Extract (CASRN 84604–20–6)
 - Milk thistle extracts are used as herbal medicines to treat a variety of diseases (e.g., liver disease) and as a food additive.
- TR 566 Diethylamine (CASRN 109–89–7)
 - Used mainly as a chemical intermediate to produce the corrosion inhibitor, N,Ndiethylethanolamine, and to lesser extent to produce pesticides, insect repellants, pharmaceuticals, and rubber processing chemicals.
- TR 567 Ginseng (CASRN 50647-08-0)
 - Ginseng is a perennial aromatic herb widely used in herbal remedies for enhancing stamina and endurance for mental and physical performance.
- TR 563 Pulegone (CASRN 89-82-7)
 - Several essential oils that contain pulegone are used for flavoring foods, drinks, and dental products, as fragrance agents, and in herbal medicines.
- TR 536 Bis(2-chloroethoxy) methane (CASRN 111–91–1)
 - Used as a solvent and as the starting agent in the production of fungicides and polysulfide polymers.

[FR Doc. E9–23781 Filed 10–1–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0664]

Oncologic Drugs Advisory Committee; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The meeting of the Oncologic Drugs Advisory Committee scheduled for October 6, 2009, is cancelled. This meeting was announced in the Federal Register of August 25, 2009 (74 FR 42907). The October 6, 2009, Oncologic Drugs Advisory Committee meeting was to discuss ApoPharma, Inc.'s new drug application (NDA) 021-825 for proposed trade name FERRIPROX (deferiprone) film-coated tablets. This meeting has been cancelled to allow time for FDA to review and resolve several outstanding issues. The agency intends to continue evaluating NDA 021-825 and, as needed, may schedule an advisory committee meeting in the

FOR FURTHER INFORMATION CONTACT:

Nicole Vesely, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–6793, FAX: 301–827– 6776, e-mail: nicole.vesely@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512542. Please call the Information Line for up-to-date information on this meeting.

Dated: September 28, 2009.

David Horowitz,

Assistant Commissioner for Policy.
[FR Doc. E9–23764 Filed 10–1–09; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Special Conflict.

Date: October 15, 2009.

Time: 1 p.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Avenue, NW., Washington, DC 20037.

Contact Person: Russell T. Dowell, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, MSC 7814, Bethesda, MD 20892. (301) 435– 1850. dowellr@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Psychopathology and Adult Disorders.

Date: October 29, 2009.

Time: 8 a.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: Parc 55 Hotel, 55 Cyril Magnin Street, Market at Fifth, San Francisco, CA 94102.

Contact Person: Biao Tian, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3089B, MSC 7848, Bethesda, MD 20892. (301) 402–4411. tianbi@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Technological Innovations for Interdisciplinary Research.

Date: October 29, 2009.

Time: 3 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Parc 55 Hotel, 55 Cyril Magnin Street, Market at Fifth, San Francisco, CA 94102.

Contact Person: Biao Tian, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3089B, MSC 7848, Bethesda, MD 20892. (301) 402–4411. tianbi@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Science Education, Communication and Childhood Disorders.

Date: October 30, 2009.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Parc 55 Hotel, 55 Cyril Magnin Street, Market at Fifth, San Francisco, CA 94102.

Contact Person: Biao Tian, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge